	US 12,465,597 B2
	Methods of treating developmental disorders with gaboxadol
Matthew During, Darien, CT (US)
Assigned to OVID THERAPEUTICS INC., New York, NY (US)
Filed by Ovid Therapeutics Inc., New York, NY (US)
Filed on Nov. 4, 2022, as Appl. No. 17/981,148.
Application 17/981,148 is a continuation of application No. 16/911,540, filed on Jun. 25, 2020, abandoned.
Application 16/911,540 is a continuation of application No. 16/451,591, filed on Jun. 25, 2019, abandoned.
Application 16/451,591 is a continuation of application No. 16/400,227, filed on May 1, 2019, abandoned.
Application 16/400,227 is a continuation of application No. 16/221,794, filed on Dec. 17, 2018, granted, now 11,096,929, issued on Aug. 24, 2021.
Application 16/221,794 is a continuation of application No. 16/053,343, filed on Aug. 2, 2018, abandoned.
Application 16/053,343 is a continuation in part of application No. 15/840,521, filed on Dec. 13, 2017, abandoned.
Application 16/053,343 is a continuation in part of application No. 15/616,460, filed on Jun. 7, 2017, abandoned.
Application 15/840,521 is a continuation of application No. 15/209,862, filed on Jul. 14, 2016, abandoned.
Claims priority of provisional application 62/346,763, filed on Jun. 7, 2016.
Claims priority of provisional application 62/332,567, filed on May 6, 2016.
Claims priority of provisional application 62/207,595, filed on Aug. 20, 2015.
Claims priority of provisional application 62/193,717, filed on Jul. 17, 2015.
Prior Publication US 2023/0071127 A1, Mar. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/437 (2006.01); A61P 25/00 (2006.01); A61P 25/14 (2006.01)

CPC A61K 31/437 (2013.01) [A61P 25/00 (2018.01); A61P 25/14 (2018.01)]

1 Claim

1. A method of treating Fragile X syndrome, said method comprising orally administering to a patient in need thereof a pharmaceutical composition comprising a compound according to formula I:

wherein about 1 mg to about 10 mg of the compound according to formula 1 is administered in a 24-hour period.